Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

24
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
24
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

23
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
23
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.4K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.4K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

25
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
25
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

1.3K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.3K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

409
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
409

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Neurodevelopmental Outcomes in Children With Congenital Heart Disease.

JAMA network open·2026
Same author

Endometriosis Pain Index: development of a model to predict poor pain-related quality of life after endometriosis surgery through machine learning analysis of registry data.

Pain·2026
Same author

Factors Affecting Hormonal Therapy Ineffectiveness and Discontinuation due to Adverse Effects in Patients with Endometriosis-Associated Pain.

Reproductive sciences (Thousand Oaks, Calif.)·2025
Same author

Circulating microRNA profiles are associated with acute pain and stress in castrated and tail docked lambs.

Veterinary and animal science·2025
Same author

Pain sensitivity questionnaire in endometriosis.

The journal of pain·2025
Same author

A review of behavioral testing in decapod shrimp (Caridea) and prawns (Dendrobranchiata) with applications for welfare assessment in aquaculture.

PeerJ·2025

Related Experiment Video

Updated: Oct 15, 2025

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

3.9K

Hepatitis D Review: Challenges for the Resource-Poor Setting.

Alice U Lee1,2, Caroline Lee3

  • 1Concord Repatriation General Hospital, University of Sydney, Sydney, NSW 2139, Australia.

Viruses
|October 26, 2021
PubMed
Summary
This summary is machine-generated.

Hepatitis D virus (HDV) infection is aggressive, requiring hepatitis B surface antigen for replication. New therapies like bulevirtide offer improved response rates, but access remains a challenge, especially in resource-limited regions.

Keywords:
hepatitis Bhepatitis Dresource limited

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.9K
Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
11:28

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques

Published on: March 13, 2015

40.9K

Related Experiment Videos

Last Updated: Oct 15, 2025

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

3.9K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.9K
Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
11:28

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques

Published on: March 13, 2015

40.9K

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis D virus (HDV) is the most severe human viral infection, necessitating hepatitis B surface antigen (HBsAg) for replication.
  • HDV affects 10-70 million people, with elimination closely linked to hepatitis B virus (HBV) control.
  • Limited data exists in resource-poor settings, and treatment options for HDV have historically been scarce and inaccessible.

Purpose of the Study:

  • To review the current landscape of Hepatitis D treatment options.
  • To highlight recent therapeutic advancements and their implications.
  • To address the challenges of accessibility in resource-limited areas.

Main Methods:

  • Review of existing literature on HDV epidemiology and treatment.
  • Analysis of recent clinical trial data for novel HDV therapeutics.
  • Discussion of treatment guidelines and access barriers.

Main Results:

  • Pegylated interferon alpha (Peg IFN α) has shown limited efficacy (20% response rate).
  • Bulevirtide (Hepcludex®), an entry inhibitor, is approved in Europe, showing >50% response rates when combined with Peg IFN α and/or nucleos(t)ide analogues.
  • Emerging therapies include lonafarnib, nucleic acid polymers, and Peg IFN lambda (λ), with promising outcomes and tolerability.

Conclusions:

  • New specific therapies for Hepatitis D, like bulevirtide, represent a significant advancement over previous treatments.
  • Despite promising results, access to these novel agents is significantly delayed in resource-limited regions.
  • Facilitating access to care for vulnerable populations affected by HDV is a critical unmet need requiring stakeholder collaboration.